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Abstract
The last two decades have seen exciting advances in understanding the human genome, aided by the
development of powerful analytical laboratory tools. These advances have enabled genome-wide association
studies to link specific genetic variants with an altered risk of cancer. Unfortunately there has not been an
analogous refinement of tools on such a comprehensive scale to permit an equally thorough investigation of
environmental factors, yet it is known that these play a major role in cancer etiology. This limitation led to the
suggested need for an exposome to match the genome. Major advances both in understanding mechanisms of
carcinogenesis as well as in the technology to investigate these underlying steps in the disease process offer the
potential to redress this imbalance between exposome and genome. This is all the more important in order to
fully exploit the large prospective cohort studies with biological specimens now being established to investigate
the environmental and genetic basis of common chronic diseases. Currently translational cancer research is
understood to equate to a “bench to bedside” process, focused on improved clinical management of cancer.
Unfortunately, alone, this is an inadequate response to the growing burden of cancer worldwide. Priority also
needs to be placed on understanding the causes of cancer, its prevention and, critically, how to implement
promising interventions into health care structures. The need therefore is to translate basic science to the
population in parallel to the translation into the clinic. This “two-way” translational cancer research encourages the
common soil of basic science to be applied both to the prevention of cancer and to its treatment. In this way the
notable advances in relation to carcinogenesis will yield a richer benefit to society through balanced initiatives to
understand the causes and prevention of cancer in addition to more effective treatment and care of those people
developing the disease.
Introduction
The last two decades have yielded unprecedented under-
standing of the human genome and subsequently pro-
gress has been made in identifying associations between
genetic variation and cancer risk [1,2]. This has been
achieved partly through the development of an exquisite
set of tools that permit a thorough characterization of
an individual’s genetic make-up in relation to their phe-
notype. Genome-wide association studies based on a
multicentre international design are therefore providing
some novel insights into the genetic variants and asso-
ciated biological pathways linked to cancer development
and response to cancer therapy.
At the same time it is pertinent to remember the criti-
cal role of environmental (i.e. non-genetic) risk factors
in the etiology of cancer [3]. The majority of cancers
have a complex causation with a number of environ-
mental factors acting on an individual’sg e n e t i cb a c k -
ground to influence risk. However, the elucidation of
these complex etiologies is often hampered by the
inability to measure environmental exposures with the
degree of precision or scope now available for genetic
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an exposome to match the genome [4,5].
The exposome is the comprehensive characterization
of an individual’s lifetime exposure history, analogous to
sequencing the 3 billion base pair genetic readout of the
genome. It can be thought of as the summation of a
sequential set of cross-sectional measurements that
would build to a composite picture of lifetime exposure.
The scope of the exposome is, by definition, broad,
including lifestyle, nutrition, occupation, obesity and
physical activity, environmental chemicals, infections,
radiation etc. The exposome is also dynamic, varying
over time both qualitatively (in composition) and quan-
titatively (in the level of a given component). Notwith-
standing the daunting task to characterize the exposome
of an individual, addressing it is now imaginable through
major advances both in understanding mechanisms of
carcinogenesis as well as through the technology avail-
able to investigate these same underlying molecular, bio-
chemical and metabolic steps in the disease process
[6,7]. Notably, it is increasingly evident that environ-
mental agents may exert their carcinogenic effects
through many diverse pathways, not only through
somatic mutation but also epigenetic changes such as
methylation, histone modification, miRNA etc [8]. It is
the more recent comprehension of these latter pathways
and the availability of tools to assess their modulation
that opens such interesting new ways to consider the
impact of the environment, in its broadest sense, on the
risk of cancer development.
Continued failure to redress the current imbalance
between the characterization of the exposome and the
genome would have serious implications for cancer pre-
vention. For example, major long-term investment has
and continues to be made to establish large-scale pro-
spective cohort studies that comprise not only complex
questionnaire and clinical data but also extensive banks
of biological material [9]. Without improvements in the
tools to measure exposure it is unlikely that the pro-
spective cohorts will yield their full promise to elucidate
the environmental and genetic components of chronic
disease as an evidence-base for prevention. It is impera-
tive therefore that investment is made now to refine a
set of tools to better investigate the environmental risk
factors for cancer so that these are available a decade
from now when the cohorts become mature in terms of
the number of cases of disease occurring among the
participants.
Biomarkers offer great promise in refining exposure
assessment, establishing the biological plausibility of an
exposure-disease association and in evaluating interven-
tion studies [5]. Biomarkers do not represent the only
opportunities for advance. For example, refinements in
personal and environmental monitoring, geographic
information systems, and increasingly sophisticated
questionnaires will provide complementary approaches
in the coming years. Nevertheless, the technologies
of genomics, transcriptomics, proteomics and metabolo-
mics offer new ways to investigate in epidemiological
studies the biological pathways relevant to carcino-
genesis [10]. In addition, developments in mass
spectrometry are permitting, for example, the more
comprehensive analysis of DNA adducts as biomarkers
of exposure [7]. These biomarkers can be detected in
the types of biological samples (plasma, serum, white
blood cells) collected in epidemiological studies and
stored in associated biobanks. The different tools there-
fore hold great promise for exposure assessment given
the accumulating evidence that a given exposure can
leave traces of its occurrence in terms of a particular
pattern of gene expression, proteins or metabolites,
although little is yet known about the duration of such
alterations, the dose-response or the influence of con-
founding factors, for example [5].
Translational cancer research is generally understood
to equate to a “bench to bedside” process. In that con-
text advances in both the knowledge of carcinogenic
mechanisms and the tools to interrogate these processes
are targeted at improving the detection, diagnosis, treat-
ment and prognosis of cancer. The goal of personalized
medicine in particular is to use this refined information
about the patient and their tumour in order to adapt
the clinical management to the individual [11]. Exam-
ples of treatment regimes tailored to novel biomarker
profiles in the tumour have already been reported [12].
The era of personalized medicine therefore provides a
tremendous opportunity for academic researchers, clini-
cians and industry to collaborate in order to develop the
cancer treatments of the future. The organizations fund-
ing cancer research also recognize the importance of
support to this research area, where donors often are
motivated by the understandable desire to “find a cure”
for cancer.
The above approach, however, has its limitations when
considered in a broader perspective. The burden of can-
cer worldwide is projected to rise dramatically in the
coming 20 years, with an estimated 12.7 million new
cases in 2008 set to rise to 21.4 million by 2030 based
on demographic changes alone [13]. This represents a
69% increase in the annual number of new cancers in
just over twenty years. For cancer deaths the projected
increase is 72%, with approximately 13.2 million deaths
in 2030 compared to 7.6 million in 2008 (Table 1).
Furthermore this burden is not evenly shared. Whilst
population aging will result in increases in cancer bur-
den in the high income countries, already over half the
new cancer cases (56%) and cancer deaths (63%) occur
in the developing regions of the world. The disparity is
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population growth and aging in these latter regions. If
the underlying incidence of cancer increases concomi-
tantly, due to more widespread tobacco use or a more
westernized lifestyle for example, then the rise and
inequality will be still more dramatic.
Consequently the greatest burden of new cancer cases
will fall on some of the regions of the world least able
to face the challenge. Improved treatment and care are
important in reducing the suffering associated with this
disease and it is therefore imperative that such services
are developed [14]. Unfortunately, alone, this is an
inadequate response. Priority also needs to be placed on
understanding the causes of cancer, its prevention and
critically, how to implement promising interventions
into health care structures.
Many risk factors and prevention strategies are already
established and in these cases implementation is the
priority (e.g. reduced tobacco use; vaccination against
hepatitis B virus and human papilloma viruses; increased
physical activity; reduced obesity; screening for cervical,
breast and colorectal cancers). However, much remains
to be understood about the complex causes of cancer
and how to intervene. These questions can be addressed
by using the laboratory tools mentioned above to
explore how risk factors act through genetic and epige-
netic pathways in the development of cancer. This new
generation of biomarkers may provide better approaches
t om e a s u r ee x p o s u r ea n dp r o v i d ee v i d e n c ea b o u tt h e
biological plausibility of an exposure-disease association.
In addition, identification of the important pathways in
human pathogenesis in relation to these exposures may
yield evidence-based opportunities to modulate the
course of disease development.
Despite the above-mentioned advances in laboratory
sciences there is a risk that the complementary opportu-
nity for cancer prevention will not be fully realized
unless the knowledge of mechanisms and the associated
technology are driven towards applied research ques-
tions in the fields of epidemiology and public health.
The need is to translate basic science to the population
in analogous fashion to the translation into the clinic.
Hence the call for “two-way” translational cancer
research [15], where the common soil of basic science is
applied both to cancer prevention and its treatment
(Figure 1). It is surely this more balanced strategy, sup-
ported by appropriate investment, which will best equip
a global response to the challenges of human cancer
burden in the next two decades.
Will the opportunities of two-way translational
research be seized? This will depend on a number of
factors some of which are highlighted here. First, there
is a need for inter-disciplinary research and the develop-
ment of a new generation of bilingual researchers com-
fortable with the languages of laboratory and population
sciences. This requires training but also structures
within and across research organizations which facilitate
and place value on such collaboration. Second, policy-
makers and funders must prioritise translational
research into the causes and prevention of cancer on a
scale not yet seen by comparison with translational
research from bench to beside. Molecular cancer epide-
miology requires a long-term investment of sufficient
magnitude to permit the incorporation of biomarker
development, validation and application into large-scale
studies. This will in turn require recognition that for the
commercial sector, investment in this type of research,
particularly primary prevention, is generally less attrac-
tive and therefore public and charitable funding should
be directed to compensate for this relative lack of mar-
ket-value. International organizations such as the Inter-
national Agency for Research on Cancer must provide
an exemplar in this regard. The longer-term benefits of
prevention in reducing the economic cost of cancer will
be an eventual counterbalance to this investment. Third,
policymakers need to be further sensitized to the
Table 1 Estimated global cancer burden in 2008 and
projections to 2030 (values in millions)
More developed Less developed World
2008 2030 2008 2030 2008 2030
New cases 5.6 7.4 7.1 12.9 12.7 21.4
Deaths 2.8 3.9 4.8 9.1 7.6 13.2
Basic Clinical Population
Mechanisms Etiology
Intervention
Early detection
Diagnosis 
Treatment
Figure 1 Two-way translational cancer research.
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as a response to the growing burden of the disease glob-
ally. Partly this requires increased support to cancer
registries to provide more complete data on the current
and future scale of the disease at a country and regional
level. Cancer prevention and control policies need to be
prioritised nationally. Fourth, the wider cancer commu-
nity needs to find more effective ways to communicate
the benefits of prevention research to the public so that
the priorities of governmental and non-governmental
organizations are influenced in this direction by the
societies they serve.
In summary, translational cancer research stands at an
exciting but critical point in time. The causes of a
majority of cancers remain unknown, limiting the evi-
dence-base for prevention. Advances in laboratory
sciences offer clear opportunities to unravel the complex
etiology of the disease, addressing both genetic and
environmental risk factors notably through improved
exposure assessment and inf o r m a t i o no nm e c h a n i s m s
which can add persuasive evidence to the causality of
exposure-disease associations. Major investments mean
that large-scale cohort studies will provide the frame-
work in which to apply many of these new tools. There
is nevertheless a period of a decade or so before the
cohorts mature in terms of numbers of cases, during
which time progress can be made in the development
and validation of the putative new biomarkers. This
challenge would be best addressed by an internationally
coordinated effort where the development of methods
aimed towards a set of “priority exposures”,a r e
addressed in an integrated way. If this were achieved the
exposome would provide not only the complement to
the genome but would mimic it in the collaborative
approach required to bring the idea to fruition.
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